Aim immunotech announces publication of positive findings from a pre-clinical study evaluating ampligen® in the treatment of pancreatic cancer in the american journal of cancer research

Findings support efforts in ongoing early access program and upcoming clinical trials, and suggest ampligen's potential to reduce tumor cell growth and boost immune response in pancreatic cancer patients with sufficient tumor levels of tlr-3 findings support efforts in ongoing early access program and upcoming clinical trials, and suggest ampligen's potential to reduce tumor cell growth and boost immune response in pancreatic cancer patients with sufficient tumor levels of tlr-3
AIM Ratings Summary
AIM Quant Ranking